Clinical and pharmacotherapeutic factors as survival and death predictors in hospitalized post-stroke patients

Q4 Neuroscience
Nancy Victoria Castilla-Torres, Zoila Díaz-Tavera, Yovani Condorhuaman-Figueroa, J. Ango-Bedriñana, Juan Kenedy Ramirez
{"title":"Clinical and pharmacotherapeutic factors as survival and death predictors in hospitalized post-stroke patients","authors":"Nancy Victoria Castilla-Torres, Zoila Díaz-Tavera, Yovani Condorhuaman-Figueroa, J. Ango-Bedriñana, Juan Kenedy Ramirez","doi":"10.31117/neuroscirn.v6i2.180","DOIUrl":null,"url":null,"abstract":"Stroke is a neurological disease. High mortality and sequelae that cause physical or psychological disability demand greater efforts for adequate therapeutic management. The present study aimed to identify signs, symptoms, comorbidities, and therapeutic agents associated with decreased survival time and increased death risk in hospitalized stroke patients. Medical records of stroke patients hospitalized in 2016 at a Peruvian hospital were included. Post-stroke survival time was determined using the Kaplan-Meier method. A comparison of the mean survival time of ischemic and hemorrhagic stroke patients was carried out with the Mantel-Cox test. In addition, the death risk or hazard ratio (HR) was determined using Cox proportional hazards model. The mean survival time was 34.37 (95% CI, 31.89-36.85) and 16.96 (95% CI, 12.35-21.56) days in post-ischemic and hemorrhagic stroke patients, respectively. Dyspnea, peripheral edema, sensory disorder, diffuse cerebral edema and previous stroke are associated with a decrease in survival time. In addition, multivariate analysis revealed that chronic kidney failure (HR=11.98; 95% CI, 2.33-61.68; p=0,003), dyslipidemia (HR=5.19; 95% CI, 1.65-16.32; p=0.005), previous stroke (HR=1.51; 95% CI, 0.41-5.63; p=0.043), and use of antihemorrhagic (HR=1.12; 95% CI, 0.79-1.59; p=0.002) or antiepileptic drugs (HR=1.08; 95% CI, 0.70-1.68; p=0.016) could be considered as death predictors. Clinical and pharmacotherapeutic factors associated with a decrease in mean survival time and increased death risk in hospitalized stroke patients were identified. These factors should be an alarm sign to provide special and timely medical care that reduces the risk of death in patients.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience Research Notes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31117/neuroscirn.v6i2.180","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Neuroscience","Score":null,"Total":0}
引用次数: 0

Abstract

Stroke is a neurological disease. High mortality and sequelae that cause physical or psychological disability demand greater efforts for adequate therapeutic management. The present study aimed to identify signs, symptoms, comorbidities, and therapeutic agents associated with decreased survival time and increased death risk in hospitalized stroke patients. Medical records of stroke patients hospitalized in 2016 at a Peruvian hospital were included. Post-stroke survival time was determined using the Kaplan-Meier method. A comparison of the mean survival time of ischemic and hemorrhagic stroke patients was carried out with the Mantel-Cox test. In addition, the death risk or hazard ratio (HR) was determined using Cox proportional hazards model. The mean survival time was 34.37 (95% CI, 31.89-36.85) and 16.96 (95% CI, 12.35-21.56) days in post-ischemic and hemorrhagic stroke patients, respectively. Dyspnea, peripheral edema, sensory disorder, diffuse cerebral edema and previous stroke are associated with a decrease in survival time. In addition, multivariate analysis revealed that chronic kidney failure (HR=11.98; 95% CI, 2.33-61.68; p=0,003), dyslipidemia (HR=5.19; 95% CI, 1.65-16.32; p=0.005), previous stroke (HR=1.51; 95% CI, 0.41-5.63; p=0.043), and use of antihemorrhagic (HR=1.12; 95% CI, 0.79-1.59; p=0.002) or antiepileptic drugs (HR=1.08; 95% CI, 0.70-1.68; p=0.016) could be considered as death predictors. Clinical and pharmacotherapeutic factors associated with a decrease in mean survival time and increased death risk in hospitalized stroke patients were identified. These factors should be an alarm sign to provide special and timely medical care that reduces the risk of death in patients.
临床和药物治疗因素作为住院卒中后患者生存和死亡的预测因素
中风是一种神经疾病。高死亡率和引起身体或心理残疾的后遗症要求为适当的治疗管理作出更大的努力。本研究旨在确定住院卒中患者与生存时间缩短和死亡风险增加相关的体征、症状、合并症和治疗药物。纳入了2016年在秘鲁一家医院住院的中风患者的医疗记录。脑卒中后生存时间采用Kaplan-Meier法测定。用Mantel-Cox试验比较缺血性脑卒中和出血性脑卒中患者的平均生存时间。此外,采用Cox比例风险模型确定死亡风险或风险比(HR)。缺血性脑卒中和出血性脑卒中患者的平均生存时间分别为34.37 (95% CI, 31.89-36.85)和16.96 (95% CI, 12.35-21.56)天。呼吸困难、外周水肿、感觉障碍、弥漫性脑水肿和既往卒中与生存时间缩短有关。此外,多因素分析显示慢性肾衰竭(HR=11.98;95% ci, 2.33-61.68;p= 0.003)、血脂异常(HR=5.19;95% ci, 1.65-16.32;p=0.005),既往卒中(HR=1.51;95% ci, 0.41-5.63;p=0.043),抗出血药的使用(HR=1.12;95% ci, 0.79-1.59;p=0.002)或抗癫痫药物(HR=1.08;95% ci, 0.70-1.68;P =0.016)可视为死亡预测因子。临床和药物治疗因素与住院卒中患者平均生存时间减少和死亡风险增加有关。这些因素应该是一个警报信号,以提供特殊和及时的医疗护理,降低患者的死亡风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuroscience Research Notes
Neuroscience Research Notes Neuroscience-Neurology
CiteScore
1.00
自引率
0.00%
发文量
21
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信